Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) CEO Michael Kauffman sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $42.50, for a total value of $8,500,000.00. Following the completion of the transaction, the chief executive officer now directly owns 587,596 shares in the company, valued at approximately $24,972,830. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Karyopharm Therapeutics (NASDAQ:KPTI) traded up 2.11% on Wednesday, hitting $45.08. 268,065 shares of the company’s stock traded hands. Karyopharm Therapeutics has a one year low of $15.50 and a one year high of $47.98. The stock has a 50-day moving average of $33.12 and a 200-day moving average of $31.81. The company’s market cap is $1.342 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings data on Wednesday, May 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.01. On average, analysts predict that Karyopharm Therapeutics will post $-2.00 earnings per share for the current fiscal year.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.